Member: RADAR on Specialty Pharmacy

To access this category, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Diplomat Mulls Strategic Options, Settles Class-Action Lawsuit

September 1, 2019

Longtime industry presence Diplomat Pharmacy, Inc. recently said it was “reviewing strategic alternatives” as the company continues to post losses. Its specialty infusion unit is doing well in a competitive industry, while its PBM unit’s struggles persist. The announcement also came a little more than a week before the company settled a class-action lawsuit for $14.1 million. It’s anyone’s guess as to what the ultimate outcome will be for the company, which went public in 2014 after almost 40 years of independence (RSP 7/14, p. 1).

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Plans Have Various Coverage Factors for Rozlytrek Beyond Cost

September 1, 2019

The FDA’s August approval of Genentech, Inc.’s Rozlytrek (entrectinib) marked the third drug approved for a tissue-agnostic oncology indication. And while one of those two legacy drugs will compete directly with the newcomer, which is priced at a much lower point, payers and providers should make coverage determinations based on more than cost alone.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Novartis, Sarepta Run Afoul of FDA, as Agency Cracks Down

September 1, 2019

A pair of drugmakers and the FDA found themselves in the news lately, but it’s safe to say it wasn’t for the reasons they would prefer. Both situations stress the importance of data needed to secure product approvals, and, perhaps, payer and provider uptake.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

New Nonmetastatic CRPC Drug Will Add to Competition in Class

with Chart: Payer responses indicate a varied approach may be taken to manage Erleada and Xtandi…

September 1, 2019

When the FDA approved Erleada (apalutamide) for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC) on Feb. 14, 2018, it was the first therapy that the agency had approved for that indication (RSP 3/18, p. 6). Following the July 30 approval of Bayer’s Nubeqa (darolutamide) (RSP 8/19, p. 8), three FDA-approved agents, all oral androgen receptor inhibitors, are available to treat the condition, offering a choice of treatment options.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

AML Therapy Class Has Seen Boom Over Past Couple of Years

September 1, 2019

The FDA has approved nearly 10 therapies for acute myeloid leukemia (AML) over the past couple of years. Because most of them target a specific biomarker, it’s critical that people diagnosed with the condition undergo genetic testing to determine whether they fall into a particular patient subgroup.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.